Centessa Pharmaceuticals plc
NASDAQ:CNTA
17.16 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 0 | 6.913 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0 | 0.236 | 0.24 | 0.248 | 0.237 | 0.238 | 0.09 | 0.036 | 0.035 | 0.032 | 0.028 | 0.012 | 0.013 | 0 | 0.002 | 0 | 0 | 0 | 0 |
Gross Profit
| 0 | -0.236 | -0.24 | 6.664 | -0.237 | -0.238 | -0.09 | -0.036 | -0.035 | -0.032 | -0.028 | -0.012 | -0.013 | 0 | -0.002 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0 | 0.964 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 33.903 | 32.815 | 22.639 | 29.975 | 28.19 | 33.673 | 32.826 | 27.835 | 36.744 | 53.651 | 36.853 | 41.534 | 25.85 | 18.134 | 10.779 | 0.994 | 2.574 | 1.871 | 3.333 |
General & Administrative Expenses
| 12.502 | 11.165 | 13.438 | 12.315 | 12.019 | 13.346 | 16.051 | 13.768 | 12.284 | 14.763 | 14.385 | 12.988 | 12.464 | 11.841 | 5.716 | 0.308 | 0.193 | 0.258 | 0.383 |
Selling & Marketing Expenses
| 0 | 0 | -0.248 | -0.141 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.523 | 0 | 0 | 0 | 0 |
SG&A
| 12.502 | 11.165 | 13.19 | 12.174 | 12.019 | 13.346 | 16.051 | 13.768 | 12.284 | 14.763 | 14.385 | 12.988 | 12.464 | 11.841 | 8.239 | 0.308 | 0.193 | 0.258 | 0.383 |
Other Expenses
| 0 | 0 | -1.537 | -0.878 | -1.677 | -1.527 | -1.346 | -0.07 | -3.143 | 5.359 | 0.196 | 0.235 | -1.906 | -0.191 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 46.405 | 43.98 | 35.83 | 42.148 | 40.209 | 47.019 | 48.877 | 41.603 | 49.028 | 68.414 | 51.238 | 54.522 | 38.314 | 29.975 | 19.019 | 3.184 | 2.038 | 2.139 | 2.925 |
Operating Income
| -46.405 | -43.98 | -36.069 | -35.484 | -40.209 | -47.019 | -48.877 | -41.603 | -49.028 | -68.414 | -53.218 | -58.292 | -38.314 | -41.287 | -19.021 | -3.005 | -2.116 | -2.129 | -3.192 |
Operating Income Ratio
| 0 | 0 | 0 | -5.133 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 4.447 | 0.869 | -1.475 | -0.515 | -1.265 | -1.918 | -1.16 | -2.234 | -4.988 | 3.731 | -1.2 | -2.368 | -1.841 | -0.164 | -221.267 | -0.281 | -0.022 | -0.099 | 0.181 |
Income Before Tax
| -41.958 | -43.111 | -37.544 | -36.003 | -41.474 | -48.937 | -50.037 | -43.837 | -54.016 | -64.683 | -54.418 | -60.66 | -40.155 | -41.451 | -240.288 | -3.286 | -2.138 | -2.228 | -3.011 |
Income Before Tax Ratio
| 0 | 0 | 0 | -5.208 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0.608 | 0.705 | 0.481 | 1.154 | -2.826 | -24.051 | 0.677 | -0.664 | -0.141 | -0.022 | 0.08 | 0.114 | -0.065 | -11.339 | 0 | 0 | -0.022 | -0.099 | 0.181 |
Net Income
| -42.566 | -43.816 | -38.024 | -37.157 | -38.648 | -24.886 | -50.714 | -43.173 | -53.875 | -64.661 | -54.498 | -60.774 | -40.155 | -41.451 | -240.288 | -3.286 | -2.138 | -2.228 | -3.011 |
Net Income Ratio
| 0 | 0 | 0 | -5.375 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.37 | -0.4 | -0.38 | -0.38 | -0.4 | -0.26 | -0.53 | -0.46 | -0.57 | -0.69 | -0.6 | -0.68 | -0.45 | -0.65 | -2.75 | -0.22 | -0.015 | 0 | 0 |
EPS Diluted
| -0.37 | -0.4 | -0.38 | -0.38 | -0.4 | -0.26 | -0.53 | -0.46 | -0.57 | -0.69 | -0.6 | -0.68 | -0.45 | -0.65 | -2.75 | -0.22 | -0.015 | 0 | 0 |
EBITDA
| -39.165 | -40.395 | -34.776 | -33.163 | -38.47 | -46.399 | -48.035 | -41.949 | -51.692 | -62.475 | -52.691 | -58.212 | -39.962 | -41.287 | -240.237 | -3.004 | -0.022 | -0.099 | 0.181 |
EBITDA Ratio
| 0 | 0 | 0 | -5.097 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |